NCT06086366

Presynaptic Imaging in Major Depressive Episodes After COVID-19

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 90 (estimated)
• Sponsor: Centre for Addiction and Mental Health · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

The goal of this observational study focuses on understanding and addressing a subset of persistent neuropsychiatric symptoms occurring within 3 months after mild to moderate COVID-19 infection (COVID-DNP). COVID-DNP encompasses major depressive episodes (MDE) with or without additional neuropsychiatric symptoms.

Detailed description

Participants will undergo two positron emission tomography (PET) scans, one \[11C\]DTBZ scan (for vesicular monoamine transporter 2 (VMAT2) and one \[18F\]SDM8 scan (for synaptic vesicle glycoprotein 2A (SV2A)), as well as one magnetic resonance imaging (MRI) scan. The main question\[s\] it aims to answer are: 1. The investigators will determine if VMAT2 binding potential (VMAT2 BPND) is reduced in ventral striatum and dorsal putamen in COVID-DNP. 2. The investigators will determine if SV2A total distribution volume (SV2A VT) is reduced in ventral striatum and dorsal putamen in COVID-DNP

Conditions

• Long COVID
• Major Depressive Disorder
• Major Depressive Episode

Interventions

Type	Name	Description
OTHER	[11C]DTBZ PET scan	One \[11C\]DTBZ scan for vesicular monoamine transporter 2 (VMAT2)
OTHER	[18F]SDM8 PET scan	One \[18F\]SDM8 scan for synaptic vesicle glycoprotein 2A (SV2A)
OTHER	MRI scan	One MRI scan

Timeline

• Start date: 2023-08-22
• Primary completion: 2028-09-10
• Completion: 2028-09-10
• First posted: 2023-10-17
• Last updated: 2026-02-11

Locations

1 site across 1 country: Canada